Project documents | Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247] | Guidance | NICE

Documents

Documents created during the development process.

Invitation to participate

Final scope (PDF 288 KB)

Published:

24 October 2018
NICE's response to comments on the draft scope and provisional matrix (PDF 473 KB)

Published:

24 October 2018
Final matrix (PDF 340 KB)

Published:

24 October 2018
Equality impact assessment (Scoping) (PDF 177 KB)

Published:

24 October 2018

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope post referral (PDF 378 KB)

Published:

24 November 2017
Draft matrix post referral (PDF 340 KB)

Published:

24 November 2017